Literature DB >> 8907774

Noninvasive screening for prenatal genetic diagnosis.

J L Simpson1.   

Abstract

During the last two decades a number of methods of prenatal diagnosis have become available and have been used either in laboratory research or in routine genetic counselling. Despite the effectiveness of invasive sampling procedures in diagnosing genetic disorders, their use involves some risk. The advantage of noninvasive methods is that they provide an opportunity to make a genetic diagnosis without risk, and therefore are applicable for use in mass screening programmes. This article reviews three different approaches to noninvasive prenatal genetic diagnosis and offers conclusions and recommendations for their use. Maternal serum screening is a well-understood technique that should be universally offered to pregnant women, regardless of their risk status. Invasive tests can be used, as indicated, once serum testing results have been obtained. Although ultrasonography cannot be recommended for routine use, it can provide a useful adjunct to serum screening and deserves further investigation. Elaboration of fetal cells from maternal blood is a promising technique but can only be considered investigational on the basis of current research, and should not serve as the sole basis of clinical decision-making.

Entities:  

Mesh:

Year:  1995        PMID: 8907774      PMCID: PMC2486681     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  20 in total

1.  First trimester prenatal diagnosis of trisomy 21 in fetal cells from maternal blood.

Authors:  S Elias; J Price; M Dockter; S Wachtel; A Tharapel; J L Simpson; K W Klinger
Journal:  Lancet       Date:  1992-10-24       Impact factor: 79.321

2.  Prenatal sex determination by DNA amplification from maternal peripheral blood.

Authors:  Y M Lo; P Patel; J S Wainscoat; M Sampietro; M D Gillmer; K A Fleming
Journal:  Lancet       Date:  1989-12-09       Impact factor: 79.321

3.  Fetal cells in the blood of pregnant women: detection and enrichment by fluorescence-activated cell sorting.

Authors:  L A Herzenberg; D W Bianchi; J Schröder; H M Cann; G M Iverson
Journal:  Proc Natl Acad Sci U S A       Date:  1979-03       Impact factor: 11.205

4.  The use of color Doppler ultrasound to identify fetuses at increased risk for trisomy 21: an alternative for high-risk patients who decline genetic amniocentesis.

Authors:  G R DeVore; O Alfi
Journal:  Obstet Gynecol       Date:  1995-03       Impact factor: 7.661

5.  Detection of fetal trisomies 21 and 18 from maternal blood using triple gradient and magnetic cell sorting.

Authors:  D Gänshirt-Ahlert; R Börjesson-Stoll; M Burschyk; A Dohr; H S Garritsen; E Helmer; P Miny; M Velasco; C Walde; D Patterson
Journal:  Am J Reprod Immunol       Date:  1993 Sep-Oct       Impact factor: 3.886

6.  The Routine Antenatal Diagnostic Imaging with Ultrasound Study: another perspective.

Authors:  G R DeVore
Journal:  Obstet Gynecol       Date:  1994-10       Impact factor: 7.661

7.  Rapid karyotyping in non-lethal fetal malformations.

Authors:  K H Nicolaides; C H Rodeck; C M Gosden
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

8.  A randomized trial of prenatal ultrasonographic screening: impact on the detection, management, and outcome of anomalous fetuses. The RADIUS Study Group.

Authors:  J P Crane; M L LeFevre; R C Winborn; J K Evans; B G Ewigman; R P Bain; F D Frigoletto; D McNellis
Journal:  Am J Obstet Gynecol       Date:  1994-08       Impact factor: 8.661

9.  Detection of fetal cells with 47,XY,+21 karyotype in maternal peripheral blood.

Authors:  D W Bianchi; A Mahr; G K Zickwolf; T W Houseal; A F Flint; K W Klinger
Journal:  Hum Genet       Date:  1992-12       Impact factor: 4.132

10.  Prenatal diagnosis from maternal blood: simultaneous immunophenotyping and FISH of fetal nucleated erythrocytes isolated by negative magnetic cell sorting.

Authors:  Y L Zheng; N P Carter; C M Price; S M Colman; P J Milton; G A Hackett; M F Greaves; M A Ferguson-Smith
Journal:  J Med Genet       Date:  1993-12       Impact factor: 6.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.